NCT01031498View on ClinicalTrials.gov

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Acute Myelogenous LeukemiaChemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Ondansetron

8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.

DRUG

Palonosetron

"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

collaborator

Eisai Inc.

INDUSTRY

NCT01031498 - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting | Biotech Hunter | Biotech Hunter